Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

[Image: see text] Epigenetic targeting has emerged as an efficacious therapy for hematological cancers. The rare and incurable T-cell prolymphocytic leukemia (T-PLL) is known for its aggressive clinical course. Current epigenetic agents such as histone deacetylase (HDAC) inhibitors are increasingly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Med Chem
Main Authors: Toutah, Krimo, Nawar, Nabanita, Timonen, Sanna, Sorger, Helena, Raouf, Yasir S., Bukhari, Shazreh, von Jan, Jana, Ianevski, Aleksandr, Gawel, Justyna M., Olaoye, Olasunkanmi O., Geletu, Mulu, Abdeldayem, Ayah, Israelian, Johan, Radu, Tudor B., Sedighi, Abootaleb, Bhatti, Muzaffar N., Hassan, Muhammad Murtaza, Manaswiyoungkul, Pimyupa, Shouksmith, Andrew E., Neubauer, Heidi A., de Araujo, Elvin D., Aittokallio, Tero, Krämer, Oliver H., Moriggl, Richard, Mustjoki, Satu, Herling, Marco, Gunning, Patrick T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2021
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8237267/
https://ncbi.nlm.nih.gov/pubmed/34101461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.1c00420
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados